SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health ($OSCR) is trending after the House passed a bill to extend ACA subsidies, sparking intense community debate on its potential for future growth and profitability, with investors keenly focused on the upcoming earnings report and crucial 2026 guidance amidst broader healthcare sector sentiment.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following strong Q4 earnings and a new share buyback, prompting community debate over its significant stock-based compensation and dilutive practices, particularly as reports circulate about Meta's Instagram developing a rival app.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining attention as recent FDA action against "copycat" GLP-1 compounded drugs highlights the value of legitimate innovation, while strong results from Eli Lilly intensify pressure on competitors like Novo Nordisk, who the community believes urgently need Viking's "best-in-class" VK2735 asset to remain competitive in the rapidly expanding obesity market.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Fiserv is trending intensely as the community eagerly anticipates its upcoming earnings, fueling a polarized debate on whether new leadership can deliver a crucial turnaround or if the stock faces continued pressure amidst broader fintech sector challenges.

Dynatrace, Inc. engages in the advancing observability for today’s digital businesses, helping to transform the complexity of modern digital ecosystems into powerful business assets. By leveraging AI-powered insights, Dynatrace enables organizations to analyze, automate, and innovate faster to drive their business forward. The company was founded by Bernd Greifeneder in 2005 and is headquartered in Boston, MA.

Dynatrace Inc

Dynatrace is trending following its strong Q3 fiscal year 2026 earnings report, which surpassed expectations across key metrics and included the authorization of a $1 billion share repurchase program. This positive financial performance and commitment to shareholder returns are fueling optimistic discussions among the community, despite some recent analyst target adjustments.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings Inc. is trending after the abrupt departures of its CFO and General Counsel amid an ongoing accounting review, an SEC investigation, and disclosures of material weaknesses in internal controls and a lowered fiscal outlook. The community is sharply divided, with many voicing deep concerns about potential fraud and a continued decline, while others are aggressively buying the significant dip, anticipating an oversold rebound.

Investment Managers Series Trust II - Tradr 2X Long CRML Daily ETF

Tradr 2X Long CRML Daily ETF

The Tradr 2X Long CRML Daily ETF ($CRMX) is actively trending following its recent launch, offering leveraged exposure to Critical Metals ($CRML) and its rare earth projects, with the community highly engaged in debate over its volatile performance and potential for significant moves.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork (UPWK) is trending sharply lower after providing a weaker-than-expected outlook, despite reporting a beat on its recent earnings. The community is actively debating if the platform is becoming obsolete due to advancing AI technology, while some view the sell-off as an overreaction and a buying opportunity.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending following strong Q4 2025 financial results and positive FY26 guidance, bolstered by recent FDA approvals for its oncology blockbusters Enhertu and Datroway, and groundbreaking Phase 3 data for hypertension treatment Baxdrostat. The community is actively discussing the company's strategic direct listing on the NYSE, along with significant investments in US manufacturing and an expanding obesity pipeline in China, all signaling a robust long-term growth outlook.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending due to the FDA's Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns over trial design, including natural history controls and the surrogate endpoint. This decision has ignited community debate, with many investors anticipating a substantial stock drop and others expressing frustration over the FDA's stringent approach to rare disease gene therapies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?

Keros Therapeutics advances KER-065 toward DMD trials, trims costs, and extends its cash runway as investors weigh it against Dyne???s deeper pipeline

FY2025 Earnings Forecast for DYN Issued By Lifesci Capital

Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Analysts at Lifesci Capital upped their FY2025 earnings per share estimates for Dyne Therapeutics in a report released on Wednesday, January 21st...

JPMorgan Chase & Co. Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $16.00

JPMorgan Chase & Co. cut their price target on shares of Dyne Therapeutics from $17.00 to $16.00 and set a "neutral" rating for the company in a research report on Tuesday...

Campbell & CO Investment Adviser LLC Purchases Shares of 64,517 Dyne Therapeutics, Inc. $DYN

Campbell & CO Investment Adviser LLC bought a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange...

Dyne Therapeutics (NASDAQ:DYN) Trading Down 4.9% - Here's What Happened

Dyne Therapeutics (NASDAQ:DYN) Trading Down 4.9% - What's Next...

Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 6% - Here's What Happened

Dyne Therapeutics (NASDAQ:DYN) Trading Down 6% - Here's What Happened...

Dyne Therapeutics (NASDAQ:DYN) Shares Down 6.7% - What's Next?

Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 6.7% - Time to Sell...

Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded Dyne Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday...

Dyne Therapeutics, Inc. $DYN Shares Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC raised its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 334.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned...

Dyne Therapeutics (NASDAQ:DYN) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen raised shares of Dyne Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Dyne Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$16.99
Prev Close	$16.80
Open	$16.64
Dividend Yield	0.00%
50-Day Moving Average	$18.90
Beta	1.85
Avg. Volume	2.22M
PE Ratio	-4.59

52-Week High	$25.00
52-Week Low	$6.36
Market Capitalization	$2.72B
EPS (Annual)	-$3.37
Price to Book	3.46
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

DYN
Dyne Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DYN News

DYNDyne Therapeutics Inc